FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma

• Status: Completed
• Trial end date: 2015-05-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate:

1. whether an imaging test called a PET (Positron emission tomography) scan performed after two cycles of standard chemotherapy is able to identify patients who have a high cure rate after completing standard chemotherapy alone; and

2. whether high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) when used in combination with an antibody called Rituximab results in high cure rates for those patients predicted to do poorly with standard chemotherapy by the PET scan.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AHS Cancer Control Alberta; Alberta Health Services
• Collaborator: Hoffmann-La Roche
• Treatments: Etoposide; Rituximab

Criteria

Inclusion Criteria:

• Age 18-65 years

• Diagnosis of Diffuse Large B-Cell Lymphoma

• Adverse Prognosis = Stage 3 or 4 and elevated LDH

• No more than one prior cycle of R-CHOP chemotherapy

• Adequate cardiac function

• No central nervous system involvement by lymphoma

Exclusion Criteria:

• Histological diagnosis other than Diffuse Large B-cell Lymphoma

• Pregnant or lactating females

• Use of other anti-cancer therapies

• Other serious illness that would compromise study participation

• Prior malignancy

• Prior stem cell transplant or radiotherapy